CIPLA Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CIPLA, and when can generic versions of CIPLA drugs launch?
CIPLA has ninety-seven approved drugs.
There are six US patents protecting CIPLA drugs. There are thirty-three tentative approvals on CIPLA drugs.
There are thirty patent family members on CIPLA drugs in twenty-one countries and four hundred and forty-two supplementary protection certificates in seventeen countries.
Summary for CIPLA
| International Patents: | 30 |
| US Patents: | 6 |
| Tradenames: | 84 |
| Ingredients: | 84 |
| NDAs: | 97 |
| Patent Litigation for CIPLA: | See patent lawsuits for CIPLA |
| PTAB Cases with CIPLA as petitioner: | See PTAB cases with CIPLA as petitioner |
Drugs and US Patents for CIPLA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cipla | AMLODIPINE BESYLATE | amlodipine besylate | TABLET;ORAL | 077073-003 | Sep 26, 2007 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cipla Usa | ZEMDRI | plazomicin sulfate | SOLUTION;INTRAVENOUS | 210303-001 | Jun 25, 2018 | RX | Yes | Yes | 8,822,424 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Cipla | FAMCICLOVIR | famciclovir | TABLET;ORAL | 078278-003 | Mar 21, 2011 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for CIPLA Drugs
Supplementary Protection Certificates for CIPLA Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0809498 | SPC/GB10/012 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112 |
| 0801067 | SPC/GB04/029 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: SOLIFENACIN AND/OR PHARMACEUTICALLY ACTIVE SALT THEREOF; REGISTERED: NL RVG 29151 20031216; NL RVG 29152 20031216; UK PL 00166/0197 20040816; UK PL 0016/0198 20040816 |
| 2203431 | 92666 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
